期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 13, 期 10, 页码 1219-1228出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2013.846830
关键词
anti-HER2 therapy; EGFR; HER2; NSCLC; oncogenic driver
类别
资金
- Italian Association for Cancer Research (AIRC)
- Associazione Oncologia Traslazionale (AOT)
In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led to the definition of different clinical entities with different therapeutic opportunities, as demonstrated in patients harboring EGF receptor (EGFR) mutations or anaplastic lymphoma kinase translocations. Human EGFR2 (or HER2) has an established role as a prognostic and predictive factor in breast cancer. Although HER2 deregulation, including overexpression, amplification and mutation, has been described in NSCLC, its role as a therapy biomarker remains undefined. In the last few years, there has been a growing interest on HER2 mutation, with few anecdotal or retrospective studies suggesting a relevant role for this biomarker. This review discusses the prognostic and predictive impact of HER2 deregulation and the clinical implications of anti-HER2 strategies in NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据